CN107635561B - 含有茶皂醇衍生物作为活性成分的组合物 - Google Patents
含有茶皂醇衍生物作为活性成分的组合物 Download PDFInfo
- Publication number
- CN107635561B CN107635561B CN201680025742.7A CN201680025742A CN107635561B CN 107635561 B CN107635561 B CN 107635561B CN 201680025742 A CN201680025742 A CN 201680025742A CN 107635561 B CN107635561 B CN 107635561B
- Authority
- CN
- China
- Prior art keywords
- composition
- skin
- theasapogenol
- active ingredient
- pores
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 118
- 229930192129 Theasapogenol Natural products 0.000 title claims abstract description 58
- 239000004480 active ingredient Substances 0.000 title claims abstract description 29
- 210000002374 sebum Anatomy 0.000 claims abstract description 25
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 19
- 244000269722 Thea sinensis Species 0.000 claims description 18
- 235000009569 green tea Nutrition 0.000 claims description 16
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 13
- 239000002537 cosmetic Substances 0.000 claims description 12
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 229960003473 androstanolone Drugs 0.000 claims description 8
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 8
- 229930182490 saponin Natural products 0.000 claims description 8
- 150000007949 saponins Chemical class 0.000 claims description 8
- 210000001732 sebaceous gland Anatomy 0.000 claims description 7
- 230000028327 secretion Effects 0.000 claims description 5
- 239000011148 porous material Substances 0.000 abstract description 43
- 230000037303 wrinkles Effects 0.000 abstract description 25
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 16
- 206010000496 acne Diseases 0.000 abstract description 16
- 230000037394 skin elasticity Effects 0.000 abstract description 14
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 238000009472 formulation Methods 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 238000007796 conventional method Methods 0.000 description 12
- 230000002708 enhancing effect Effects 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- -1 foundation Substances 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 229960003604 testosterone Drugs 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000036570 collagen biosynthesis Effects 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 235000013616 tea Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229930185549 teaseedsaponin Natural products 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241001467578 Microbacterium Species 0.000 description 2
- 241000235575 Mortierella Species 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000235402 Rhizomucor Species 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000228341 Talaromyces Species 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- 239000013538 functional additive Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical class NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- BWSWZBCSFZAYOB-CABCVRRESA-N (2s,4r)-1-dodecanoyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCC(=O)N1C[C@H](O)C[C@H]1C(O)=O BWSWZBCSFZAYOB-CABCVRRESA-N 0.000 description 1
- TXJTZIIDMZBTEB-UHFFFAOYSA-N (3alpha,11alpha)-3,11,23-Trihydroxy-20(29)-lupen-28-oic acid Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CC(O)C3C21C TXJTZIIDMZBTEB-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 229930185199 Sapogenol Natural products 0.000 description 1
- PDCALJUWWJEWKR-UHFFFAOYSA-N Saponin E3 Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OCC(O)C(O)C1O PDCALJUWWJEWKR-UHFFFAOYSA-N 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108010084650 alpha-N-arabinofuranosidase Proteins 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical class CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000033687 granuloma formation Effects 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 108010030923 hesperidinase Proteins 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 108010001078 naringinase Proteins 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- OWGHQYPQNSZTFQ-UHFFFAOYSA-M triethyl(octadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](CC)(CC)CC OWGHQYPQNSZTFQ-UHFFFAOYSA-M 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
- A61K8/0225—Granulated powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Birds (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明说明书公开用于收紧毛孔、抑制或改善皱纹、促进皮肤弹性、调节皮脂和预防或改善痤疮皮肤的组合物，作为一个实施方案，所述组合物含有茶皂醇衍生物21‑O‑当归酰基茶皂醇E3作为活性成分。
Description
[技术领域]
本发明说明书公开用于收紧毛孔、抑制或改善皱纹、增强皮肤弹性、控制皮脂和预防或改善痤疮皮肤的组合物，其含有茶皂醇(theasapogenol)衍生物作为活性成分。
[背景技术]
根据皮肤表面的状态，将皮肤分为各种类型，诸如干性型、中性型、油性型和复合型，这取决于NMF(天然保湿因子)和皮脂的量。当NMF和皮脂的量很好地均衡时皮肤保持湿润和柔软的状态，但当皮脂分泌过多时很可能是油性皮肤或痤疮皮肤。油性皮肤在皮肤表面有毛孔，使得毛孔展现出有大量的皮脂分泌到皮肤表面，面部看起来很脏，以及面部化妆品容易被去除。
因此，需要开发克服这样的问题的物质，从而具有缓解由皮脂分泌引起的皮肤不舒适，清爽皮肤和减少皮肤刺激的功能。
真皮是由表皮下方的结缔组织组成的部分，并由称为细胞外基质的大分子网络填充。构成细胞外基质的部分是由被称为葡糖胺聚糖或粘多糖的多糖、胶原蛋白和弹性蛋白组成的纤维蛋白。其中，胶原蛋白是构成细胞外基质的主要蛋白质并作用于保持组织的形态，因此真皮对皮肤的弹性和拉伸强度有很大的影响。因此，当由于外部或内部影响导致胶原蛋白损伤时，皱纹形成或皮肤弹性降低以及皮肤松弛。这也是改善皱纹的化妆品最近也使用增加胶原蛋白合成的组分(如视黄醇)的原因。
此外，毛孔大小的增加是真皮的基质结构松弛以及毛孔周围皮肤松弛的现象。真皮含有血管、神经、毛发、二头肌(也称为不对称根)、汗腺和皮脂腺。皮脂腺不断地产生皮脂并分泌皮脂通过毛孔从皮脂腺的排泄道(excretory drift)到皮肤表面。此时，可能在毛孔中引起角化过度(角质化非正常地进行以及脱离延迟的现象)，毛囊中增厚的角质层剥离，堵塞毛孔，导致皮脂保留在毛囊中，因此引起皮疹和炎症，以及形成肉芽肿留下痕迹。
因此，为了有效地收紧增大的毛孔，需要除去毛孔上的由于异常角质化过程而加厚的角蛋白，以激活细胞代谢，同时促进真皮组织的胶原蛋白的产生，从而恢复凹陷或增大的毛孔的结构。
同时，5α-还原酶存在于雄性激素-反应性组织诸如皮脂腺、毛囊、前列腺、附睾，并且是参与睾酮(雄性激素之一)还原成二氢睾酮(DHT)的酶，这个转换中需要NADPH。睾酮与男性性功能障碍、骨骼肌增加、男性外生殖器、阴囊生长和精子发生有关，二氢睾酮与痤疮、增加皮脂和相应组织中的前列腺增大有关(Sugimoto et al；J.I.D.Vol.104,No.5,775-778,1995.Bruchovsky,N.等人,J.B.C.243,2012-2021,1968)。
因此，为了抑制由5α-还原酶产生的二氢睾酮引起的副作用，正在进行研究以开发通过使用5α-还原酶酶类抑制剂的痤疮治疗剂和皮脂分泌抑制剂。
相关现有技术包括韩国专利号10-1415995。
[发明概述]
[技术问题]
一方面，本发明意在提供含有茶皂醇衍生物作为活性成分的组合物，其促进胶原蛋白生物合成并且因此具有收紧毛孔(或皮肤毛孔)、抑制或改善皱纹(或皮肤皱纹)和增强皮肤弹性的优异效果。
另一方面，本发明意在提供含有茶皂醇衍生物作为活性成分的组合物，其抑制5α-还原酶活性并且因此具有控制皮脂和预防或改善痤疮皮肤的优异效果。
[解决问题的方案]
[化学式1]
(其中R1和R2各自独立地是-H、C1-6烷基、-OH、-R6OH或-CHO，
R3是-H、C1-6烷基、-OH或-OOCR7，
R4是-H或-COR8，且
R5是-H或C1-6烷基，
其中R6是C1-6烷基，R7是C2-6烯基，且R8是C1-6烷基)。
一方面，本文公开的技术提供用于收紧毛孔(或皮肤毛孔)的组合物，其含有由化学式(1)表示的茶皂醇衍生物作为活性成分。
另一方面，本文公开的技术提供用于抑制或改善皱纹(或皮肤皱纹)的组合物，其含有由化学式(1)表示的茶皂醇衍生物作为活性成分。
再一方面，本文公开的技术提供用于增强皮肤弹性的组合物，其含有由化学式(1)表示的茶皂醇衍生物作为活性成分。
又一方面，本文公开的技术提供用于控制皮脂的组合物，其含有由化学式(1)表示的茶皂醇衍生物作为活性成分。
再又一方面，本文公开的技术提供用于预防或改善痤疮皮肤的组合物，其含有由化学式(1)表示的茶皂醇衍生物作为活性成分。
根据一方面，本文公开的技术提供由化学式(1)表示的茶皂醇衍生物，其用于一种或多种选自收紧毛孔(或皮肤毛孔)、抑制或改善皱纹(或皮肤皱纹)、增强皮肤弹性、控制皮脂和预防或改善痤疮皮肤的应用。
再一方面，本文公开的技术提供一种或多种方法，所述方法选自收紧毛孔(或皮肤毛孔)的方法、抑制或改善皱纹(或皮肤皱纹)的方法、增强皮肤弹性的方法、控制皮脂的方法和预防或改善痤疮皮肤的方法，所述方法包括给有此需要的个体施用由化学式(1)表示的茶皂醇衍生物或含有所述茶皂醇衍生物作为活性成分的组合物，并且具有一种或多种选自收紧毛孔(或皮肤毛孔)、抑制或改善皱纹(或皮肤皱纹)、增强皮肤弹性、控制皮脂和预防或改善痤疮皮肤的应用。一方面，可根据本文描述的施用方法和剂量进行施用。
另一方面，本文公开的技术提供由化学式(1)表示的茶皂醇衍生物的应用，用于制备用于一种或多种选自收紧毛孔(或皮肤毛孔)、抑制或改善皱纹(或皮肤皱纹)、增强皮肤弹性、控制皮脂和预防或改善痤疮皮肤的应用的组合物。
根据示例性实施方案，茶皂醇衍生物可以是21-O-当归酰基茶皂醇E3。
根据示例性实施方案，21-O-当归酰基茶皂醇E3可由以下化学式(2)表示。
[化学式2]
根据示例性实施方案，茶皂醇衍生物可衍生自绿茶皂苷。
根据示例性实施方案，活性成分的含量可以是基于组合物总重量的0.001重量％至20重量％。
根据示例性实施方案，组合物可促进胶原蛋白生物合成。
根据示例性实施方案，组合物可抑制5α-还原酶活性。
根据示例性实施方案，组合物可以是药物组合物。
根据示例性实施方案，组合物可以是化妆品组合物。
根据示例性实施方案，组合物可以是食品组合物。
[发明的有益效果]
一方面，本文公开的技术具有以下效果：提供含有促进胶原蛋白生物合成并且因此具有收紧毛孔(或皮肤毛孔)、抑制或改善皱纹(或皮肤皱纹)和增强皮肤弹性的优异效果的茶皂醇衍生物作为活性成分的组合物。
另一方面，本文公开的技术具有以下效果：提供含有抑制5α-还原酶活性并且因此具有控制皮脂和预防或改善痤疮皮肤的优异效果的茶皂醇衍生物作为活性成分的组合物。
再一方面，本文公开的技术具有以下效果：提供用于收紧毛孔(或皮肤毛孔)、抑制或改善皱纹(或皮肤皱纹)、增强皮肤弹性、控制皮脂和预防或改善痤疮皮肤的药物组合物、化妆品组合物和食品组合物，其含有衍生自植物的天然物质的茶皂醇衍生物作为活性成分，因此没有副作用并表现出优异的稳定性。
[具体实施方案]
以下，会详细描述本发明。
[化学式1]
(其中R1和R2各自独立地是-H、C1-6烷基、-OH、-R6OH或-CHO，
R3是-H、C1-6烷基、-OH或-OOCR7，
R4是-H或-COR8，且
R5是-H或C1-6烷基，
其中R6是C1-6烷基，R7是C2-6烯基，且R8是C1-6烷基)。
一方面，本文公开的技术提供用于收紧毛孔(或皮肤毛孔)的组合物，其含有由化学式(1)表示的茶皂醇衍生物作为活性成分。
另一方面，本文公开的技术提供用于抑制或改善皱纹(或皮肤皱纹)的组合物，其含有由化学式(1)表示的茶皂醇衍生物作为活性成分。
再一方面，本文公开的技术提供用于增强皮肤弹性的组合物，其含有由化学式(1)表示的茶皂醇衍生物作为活性成分。
又一方面，本文公开的技术提供用于控制皮脂的组合物，其含有由化学式(1)表示的茶皂醇衍生物作为活性成分。
再又一方面，本文公开的技术提供用于预防或改善痤疮皮肤的组合物，其含有由化学式(1)表示的茶皂醇衍生物作为活性成分。
根据示例性实施方案，茶皂醇衍生物可以是21-O-当归酰基茶皂醇E3。
根据示例性实施方案，21-O-当归酰基茶皂醇E3可由以下化学式(2)表示。化学式2相当于由化学式(1)表示的茶皂醇衍生物，其中R1是-CHO，R2是-CH3，R3是-OCOC(CH3)＝CHCH3，R4是-COCH3，且R5是-CH3。
[化学式2]
根据示例性实施方案，茶皂醇衍生物可衍生自绿茶皂苷，更具体地衍生自绿茶籽皂苷。衍生自绿茶籽皂苷的茶皂醇衍生物可通过以下制造方法制造，其包括：通过使用水或有机溶剂从绿茶籽中获得含有皂苷的提取物的步骤；和用酸、碱、酶或产生该酶的微生物水解提取物以分离茶皂醇衍生物(更具体地，21-O-当归酰基茶皂醇E3)的步骤。
作为有机溶剂，可以使用选自乙醇、甲醇、丁醇、乙醚、乙酸乙酯和氯仿的一种或多种有机溶剂或者它们与水的任何混合物，一方面可以使用50％的乙醇。
作为酸，可以使用选自盐酸、硫酸和硝酸的一种或多种酸或者所述酸与选自乙醇、甲醇和丁醇的一种或多种醇的任何混合溶剂。
作为碱，可以使用选自氢氧化钠和氢氧化钾的一种或多种碱或者所述碱与选自乙醇、甲醇和丁醇的一种或多种醇的任何混合溶剂。
酶或产生该酶的微生物是分解提取物中所含的绿茶皂苷的糖结合的酶或是产生分解所述糖结合的酶的微生物，其可除去绿茶皂苷的糖部分以产生茶皂醇衍生物，更具体地，21-O-当归酰基茶皂醇E3。
此外，酶可以是选自葡糖苷酶、阿拉伯糖苷酶、鼠李糖苷酶、木糖苷酶、纤维素酶、橙皮苷酶、柚皮苷酶、葡糖醛酸糖苷酶、果胶酶、半乳糖苷酶和淀粉葡糖苷酶的一种或多种。
此外，产生该酶的微生物可以是选自曲霉属(Aspergillus)、芽孢杆菌属(Bacillus)、青霉属(Penicillium)、根霉属(Rhizopus)、根毛霉属(Rhizomucor)、篮状菌属(Talaromyces)、双歧杆菌属(Bifidobacterium)、被孢霉属(Mortierella)、隐球菌属(Cryptococcus)和微杆菌属(Microbacterium)的一种或多种。
如上所述，通过使用酸、碱、酶或产生该酶的微生物进行水解，将反应液减压浓缩以除去溶剂，向残余物中加入醇，并搅拌混合物1至5次，然后通过过滤除去沉淀的盐，将滤液减压浓缩以得到粗产物，将由此获得的粗产物通过硅胶柱层析(氯仿:甲醇＝8:1至4:1)分离，从而获得21-O-当归酰基茶皂醇E3。
一方面，制造衍生自绿茶皂苷的茶皂醇的方法公开于韩国专利申请号10-2008-0088127中，其全部内容援引加入本文。
根据示例性实施方案，活性成分的含量可以是基于组合物总重量的0.001重量％至20重量％。根据另一示例性实施方案，活性成分的含量可以是基于组合物总重量的0.01重量％至15重量％、0.01重量％至10重量％或0.1重量％至5重量％。
一方面，本文公开的组合物中含有的由化学式(1)表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3的含量可以是基于组合物总重量的0.001重量％或更高、0.01重量％或更高、0.1重量％或更高或者1.0重量％或更高。另一方面，茶皂醇衍生物或21-O-当归酰基茶皂醇E3的含量可以是基于组合物总重量的20重量％或更低、15重量％或更低、10重量％或更低或者5重量％或更低。含量不特别限于上述含量，但当含量是0.001重量％或更高时，组合物表现出收紧毛孔(或皮肤毛孔)、改善皱纹(或皮肤皱纹)、增强皮肤弹性、控制皮脂和改善痤疮的优异效果。当含量是20重量％或更低时，容易确保安全性或容易将组合物制造成制剂，并且表现出优异的有效性而没有副作用。
根据示例性实施方案，组合物可促进胶原蛋白生物合成。更具体地，组合物可增加成纤维细胞的I型前胶原的合成。
根据示例性实施方案，组合物可抑制5α-还原酶活性。
根据示例性实施方案，组合物可以是药物组合物。
除由化学式(1)表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3外，药物组合物可另外含有防腐剂、稳定剂、润湿剂或乳化剂、用于控制渗透压的药物辅剂如盐和/或缓冲剂，和其他治疗上有用的物质。药物组合物可通过常规方法配制成各种形式的口服或肠胃外施用剂。
口服施用剂的实例可包括片剂、丸剂、硬胶囊剂和软胶囊剂、液体、混悬剂、乳剂、糖浆剂、散剂、粉末治疗剂(powder remedies)、极微颗粒剂、颗粒剂和丸剂。除活性成分外，这些制剂可含有表面活性剂、稀释剂(例如，乳糖、葡萄糖、蔗糖、甘露醇、山梨醇、纤维素或甘氨酸)和润滑剂(例如，硅石、滑石、硬脂酸及其镁盐或钙盐和聚乙二醇)。片剂还可含有粘合剂，诸如硅酸铝镁、淀粉浆、明胶、黄芪胶、甲基纤维素、羧甲基纤维素钠或聚乙烯吡咯烷酮。片剂可任选地含有药用添加剂(诸如淀粉、琼脂)、崩解剂(诸如海藻酸或其钠盐)、吸收剂、着色剂、调味剂和甜味剂。片剂可通过常规的混合、制粒或包衣方法制造。
此外，肠胃外施用形式可以是透皮施用形式，例如，肠胃外施用形式可以是制剂，诸如注射剂、滴剂、软膏剂、洗剂、凝胶剂、乳膏、喷雾剂、混悬剂、乳剂、栓剂和贴剂，但不限于此。
药物组合物可以经肠胃外形式、直肠形式、局部形式、透皮形式、皮下形式等施用。根据本发明实施方案的药物组合物可以是局部施用，例如，施用至头皮。
活性成分的剂量由本领域技术人员确定，药物的日剂量取决于施用的个体的各种因素，诸如进展程度、发病时间、年龄、健康状况、并发症等。当给成年人施用时，每天一至三次施用，一方面可按1μg/kg至200mg/kg的量施用，另一方面可按50μg/kg至50mg/kg的量施用。剂量不意在以任何方式限制本发明的范围。
药物组合物可以是皮肤的外用制剂，皮肤的外用制剂是通用术语，其可包含从皮肤外应用的任何制剂，并且其中包括药物的各种制剂。
根据示例性实施方案，组合物可以是化妆品组合物。
除由化学式(1)表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3外，化妆品组合物可另外含有一般化妆品组合物含有的功能添加剂和组分。功能添加剂可包括选自水溶性维生素、油溶性维生素、聚合物肽、聚合多糖、鞘脂和海藻提取物的组分。除了这些之外另外混合的组分的实例可包括油脂组分、保湿剂、润肤剂、表面活性剂、有机和无机色素、有机粉末、紫外线吸收剂、防腐剂、杀菌剂、抗氧化剂、植物提取物、pH调节剂、醇、着色剂、香料、血液循环促进剂、冷却剂、止汗剂和纯净水。
化妆品组合物的制剂没有特别的限制，且可根据目的适当地选择。例如，化妆品组合物可制备成任何选自皮肤洗剂、皮肤柔软剂、皮肤调色剂(skin toner)、收敛剂、洗剂、乳液、保湿乳液、滋润乳液、按摩膏、营养霜、护手霜、粉底、精华、滋润精华、面膜、皂、清洁泡沫、卸妆乳、清洁霜、身体乳液和沐浴液的一种或多种制剂，但不限于此。
在本发明的制剂是糊剂、乳膏或凝胶剂的情况下，动物纤维、植物纤维、蜡、石蜡、淀粉、黄芪胶、纤维素衍生物、聚乙二醇、硅酮、膨润土、硅石、滑石或氧化锌可用作载体组分。
在本发明的制剂是散剂或喷雾剂的情况下，乳糖、滑石、硅石、氢氧化铝、硅酸钙或聚酰胺粉末可用作载体组分。特别地，在喷雾剂的情况下，可另外包含抛射剂，诸如氯氟烃、丙烷/丁烷或二甲醚。
在本发明的制剂是溶液剂或乳剂的情况下，溶剂、溶媒或乳化剂用作载体组分。其实例可包括水、乙醇、异丙醇、碳酸乙酯、乙酸乙酯、苯甲醇、苯甲酸苄酯、丙二醇、1,3-丁二醇油、甘油脂肪酸酯、聚乙二醇或脱水山梨醇脂肪酸酯。
在本发明的制剂是混悬剂的情况下，液体稀释剂诸如水、乙醇或丙二醇、助悬剂诸如乙氧基化异硬脂醇、聚氧乙烯山梨醇酯或聚氧乙烯脱水山梨醇酯、微晶纤维素、偏氢氧化铝(aluminum metahydroxide)、膨润土、琼脂、黄芪胶等可用作载体组分。
在本发明的制剂是含表面活性剂的清洁剂的情况下，脂肪醇硫酸盐、脂肪醇醚硫酸盐、磺基琥珀酸单酯、羟乙基磺酸盐、咪唑啉盐衍生物、甲基牛磺酸盐、肌氨酸盐、脂肪酸酰胺醚硫酸盐、烷基酰胺甜菜碱、脂肪醇、脂肪酸甘油酯、脂肪酸二乙醇酰胺、植物油、亚麻酸衍生物或乙氧基甘油脂肪酸酯可用作载体组分。
根据示例性实施方案，组合物可以是食品组合物。
食品组合物可以是液体或固体状态的制剂。其实例可包括各种食品、饮料、胶(gum)、茶、维生素复合物和健康补充食品(health supplement food)。食品组合物可以散剂、颗粒剂、片剂、胶囊剂或饮料的形式使用。除了活性成分外，本领域技术人员可根据制剂或使用目的无困难地适当地选择和混合本领域通常使用的除活性成分外的组分在食品组合物的每种制剂中。当食品组合物与其它原料同时应用时可获得协同效应。
对于除本文公开的活性成分外的可含有的液体组分没有特别限制，并且可作为额外的组分包含各种调味剂或天然碳水化合物，如同在普通饮料中一样。天然碳水化合物的实例可包括糖类(诸如单糖、二糖(诸如葡萄糖和果糖)、多糖(诸如麦芽糖和蔗糖)、糊精和环糊精)和糖醇(诸如木糖醇、山梨糖醇和赤藓糖醇)。作为调味剂，可以有利地使用天然调味剂(奇异果甜蛋白、甜叶菊提取物(例如，莱鲍迪甙A(rebaudioside A)或甘草皂苷))和合成调味剂(例如，糖精和阿斯巴甜)。天然碳水化合物的比率通常可以是每100ml本文公开的组合物中约1g至20g，一方面约5g至12g。
一方面，食品组合物可含有各种营养素、维生素、矿物质(电解质)、调味剂(诸如合成调味剂和天然调味剂)、着色剂和增强剂(奶酪、巧克力等)、果胶酸和其任何盐、海藻酸和其任何盐、有机酸、保护性胶体增稠剂、pH调节剂、稳定剂、防腐剂、甘油、醇和用于碳酸饮料中的碳酸化剂。另一方面，食品组合物可含有产生天然果汁和植物饮料的果肉。这些组分可以单独使用或组合使用。添加剂的比例可以是各种各样的，但通常添加剂选择范围是按重量每100份本文公开的组合物约0.001至约20份。
[实施例]
以下，会参考实施例更详细地描述本发明。这些实施例仅用于说明本发明，并且对于本领域技术人员显而易见的是，本发明的范围不应解释为限于这些实施例。
制备例1.茶皂醇衍生物的制备
向2kg绿茶籽中加入6L己烷，并将混合物在室温下搅拌脱脂。其后，向1kg脱脂绿茶籽中加入4L 50％乙醇，将混合物回流三次以提取，然后在15℃下浸渍一天。其后，通过滤布过滤和离心分离残余物和滤液，将分离的滤液减压浓缩，将由此获得的提取物在水中悬浮，然后用1L乙醚提取五次以除去色素，水层用500ml 1-丁醇提取三次。将由此获得的整个1-丁醇层减压浓缩以获得1-丁醇提取物，将其在少量甲醇中溶解，然后将溶液加入到大量乙酸乙酯中，并干燥由此形成的沉淀，从而获得300g绿茶籽提取物。
向由此获得的10g绿茶籽提取物中加入1N HCl-50％甲醇溶液(v/v)以至提取物的20倍(v/w)，在80℃水浴中加热并回流混合物8小时以水解结合到绿茶籽皂苷的糖。将反应液减压浓缩以除去溶剂。向残余物中加入乙醇(200ml)，搅拌混合物(3次)，通过过滤除去沉淀的盐，并将滤液减压浓缩以获得粗产物。其后，将由此获得的粗产物通过硅胶柱层析(氯仿:甲醇＝7:1至3:1)分离，从而获得0.55g茶皂醇衍生物21-O-当归酰基茶皂醇E3。
已通过使用Varian Gemini 2000 300MHz(Varian)确认产物是21-O-当归酰基茶皂醇E3。因此，获得与本文所引用的专利申请号10-2008-0088127的详细说明的实验例1中相同的结果。
测试例1.促进胶原蛋白生物合成
与阳性对照TGF-beta相比，测量制备例1中获得的茶皂醇衍生物的胶原蛋白生物合成促进作用。
在24孔板的一个孔中以105接种成纤维细胞，并孵育直至它们长到约90％。将其在无血清DMEM培养基中孵育24小时，并用2μg/ml的制备例1中获得的茶皂醇衍生物和TGF-beta各自处理，并在CO2培养箱中孵育24小时。其后，取出上清液并使用ELISA试剂盒(前胶原(I)型)进行观察以确定前胶原是增加还是减少。结果在表1中呈现，通过将未处理组的胶原蛋白合成能力设定为100来比较胶原蛋白合成能力。
[表1]
| 分组(Division) | 胶原蛋白合成能力(％) |
| 未处理组 | 100 |
| TNF-beta | 183.5±13.1 |
| 制备例1 | 145.1±12.5 |
从上表1中所示的结果，已确认本文公开的茶皂醇衍生物表现出高的胶原蛋白合成能力。因此，可以看出本文公开的茶皂醇衍生物增加毛孔(或皮肤毛孔)周围产生的胶原蛋白的量，从而具有收紧增大的皮肤毛孔、抑制或改善皮肤皱纹和增强皮肤弹性的效果。
测试例2.抑制5α-还原酶活性
通过HEK293-5αR2细胞中[14C]睾酮转换成[14C]二氢睾酮的比率测量5α-还原酶活性抑制效果。
用p3×FLAG-CMV-5αR2转染HEK293细胞，并以每孔2.5×105个细胞的密度在24孔板中孵育(Park等人,2003,JDS Vol.31,pp.91-98)。第二天，用含酶底物和抑制剂的新鲜培养基替换培养基，并使用0.05μCi[14C]睾酮(Amersham Pharmacia biotech,UK)作为培养基底物。为了确认抑制程度，将2μg/ml制备例1中获得的茶皂醇衍生物加入到培养基中作为测试物质，并将培养基在5％CO2培养箱中于37℃孵育2小时。为了比较，使用不含任何测试物质的培养基作为阴性对照组，并使用通过向培养基中加入2μg/ml非那雄胺并在相同条件下孵育培养基制备的培养基作为阳性对照组。
其后，收集孵育的培养基并用800μl乙酸乙酯提取睾酮。分离和干燥上面的有机溶剂层，将残余物在50μl乙酸乙酯中再次溶解，并使用乙酸乙酯-己烷(1:1)作为显影溶剂在硅胶薄片kieselgel 60F254上显影。在薄片样品在空气中干燥后，使用浴系统来测量同位素的量，将干燥的薄片和x-射线胶片一起放在浴盒中，并在一周后检测胶片上剩余的睾酮和二氢睾酮中同位素的量。结果在下表2中呈现。
[表2]
| 样品 | 转换率(％) | 抑制率(％) |
| 制备例1 | 30 | 38 |
| 对照组 | 48 | - |
| 阳性对照(非那雄胺) | 27 | 44 |
(1)转换率：对DHT面积的放射性/总放射性
(2)抑制率：100×(对照组的转换率-样品的转换率)/对照组的转换率
可以看出，作为有效性评价的结果，本文公开的茶皂醇衍生物比对照组表现出更优的5α-还原酶活性抑制效果，因此具有控制皮脂和预防或改善痤疮皮肤的优异效果。
从上表2中所示的结果，可以看出茶皂醇衍生物通过有效抑制5α-还原酶(其将睾酮转换成二氢睾酮，结合细胞质中的受体蛋白，进入细胞核，激活皮脂腺细胞，促进分化，并引起皮脂腺中皮脂的过度分泌)活性阻断睾酮转换成二氢睾酮。因此，本文公开的茶皂醇衍生物具有抑制5α-还原酶活性、抑制皮脂的过度分泌、控制皮脂和预防或改善痤疮的效果。
测试例3.收紧皮肤毛孔
通过使用制备例1中获得的茶皂醇衍生物如下制备洗剂制剂(单位：重量％)的实施例和比较例。
[表3]
1)将组分11至14均匀混合同时加热到70℃以制备水相部分。
2)将组分1至10均匀混合同时加热到70℃以制备油相部分。
3)将油相部分2)加入到水相部分1)中并在7,200rpm下均匀混合6分钟。
4)将3)的混合物冷却至室温。
将由此制备的实施例和比较例的洗剂制剂每天应用于有宽毛孔大小的10个男性和女性个体面部4周。通过实验前和实验开始后4周面部拍照并由专家视觉评估区别来对毛孔收紧效果进行评价。结果在表4中呈现(评估标准：0(毛孔完全未收紧)至5(毛孔显著收紧))。
[表4]
| 物质 | 评估等级 |
| 实施例 | 3.2 |
| 比较例 | 0.8 |
在含有制备例1中获得的茶皂醇衍生物的实施例的情况下，获得毛孔收紧的效果。然而，在不含有茶皂醇衍生物的比较例的情况下，没有毛孔收紧的效果，因为评估等级是0.8。从上述结果可以发现本文公开的茶皂醇衍生物具有优异的毛孔收紧效果。
以下描述根据本发明的一方面的组合物的制剂例，但是组合物可应用于各种其他制剂，且制剂例并不意在限制本发明，而仅用于说明本发明。
[制剂例1]洗发水
通过常规方法制备洗发水以具有下表5中呈现的组成。
[表5]
[制剂例2]护发素
通过常规方法制备护发素以具有下表6中呈现的组成。[表6]
| 组分 | 含量(重量％) |
| 由化学式(1)表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 2.00 |
| 鲸蜡醇 | 2.00 |
| 硬脂醇 | 2.50 |
| 二十二烷醇 | 0.50 |
| 硅酮乳液 | 0.40 |
| 环甲基硅油 | 1.00 |
| 二甲基二硬脂基氯化铵 | 0.10 |
| 纯净水 | 余量 |
| 总共 | 100.00 |
[制剂例3]软膏剂
通过常规方法制备软膏剂以具有下表7中呈现的组成。[表7]
[制剂例4]生发油(Hair Tonic)
通过常规方法制备生发油以具有下表8中呈现的组成。[表8]
| 组分 | 含量(重量％) |
| 乙醇 | 55.0 |
| 蓖麻油 | 5.00 |
| 甘油 | 3.00 |
| 吡罗克酮乙醇胺盐 | 0.10 |
| 由化学式(1)表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 1.00 |
| 香料和着色剂 | 适量 |
| 纯净水 | 余量 |
| 总共 | 100.00 |
[制剂例5]发乳(Hair Lotion)
通过常规方法制备发乳以具有下表9中呈现的组成。[表9]
| 组分 | 含量(重量％) |
| 鲸蜡硬脂醇 | 2.00 |
| 硬脂基三乙基氯化铵 | 2.00 |
| 羟乙基纤维素 | 0.50 |
| 吡罗克酮乙醇胺盐 | 0.10 |
| 由化学式(1)表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 10.0 |
| 香料和着色剂 | 0.50 |
| 纯净水 | 余量 |
| 总共 | 100.00 |
[制剂例6]皂
通过常规方法制备皂以具有下表10中呈现的组成。
[表10]
[制剂例7]洗剂
通过常规方法制备洗剂以具有下表11中呈现的组成。[表11]
| 组分 | 含量(重量％) |
| 由化学式(1)表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 2.00 |
| L-抗坏血酸-2-磷酸镁盐 | 1.00 |
| 水溶性胶原蛋白(1％水溶液) | 1.00 |
| 柠檬酸钠 | 0.10 |
| 柠檬酸 | 0.05 |
| 甘草提取物 | 0.20 |
| 1,3-丁二醇 | 3.00 |
| 纯净水 | 余量 |
| 总共 | 100.00 |
[制剂例8]乳膏
通过常规方法制备乳膏以具有下表12中呈现的组成。[表12]
| 组分 | 含量(重量％) |
| 由化学式(1)表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 2.00 |
| 聚乙二醇单硬脂酸酯 | 2.00 |
| 自乳化单硬脂酸甘油酯 | 5.00 |
| 鲸蜡醇 | 4.00 |
| 角鲨烯 | 6.00 |
| 三-2-乙基己酸甘油酯(Tri-2-ethylhexane glyceryl) | 6.00 |
| 神经鞘糖脂 | 1.00 |
| 1,3-丁二醇 | 7.00 |
| 纯净水 | 余量 |
| 总共 | 100.00 |
[制剂例9]面膜
通过常规方法制备面膜以具有下表13中呈现的组成。
[表13]
| 组分 | 含量(重量％) |
| 由化学式(1)表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 2.00 |
| 聚乙烯醇 | 13.00 |
| L-抗坏血酸-2-磷酸镁盐 | 1.00 |
| 十二烷酰基羟脯氨酸 | 1.00 |
| 水溶性胶原蛋白(1％水溶液) | 2.00 |
| 1,3-丁二醇 | 3.00 |
| 乙醇 | 5.00 |
| 纯净水 | 余量 |
| 总共 | 100.00 |
[制剂例10]化妆品液体制剂
通过常规方法制备化妆品液体制剂以具有下表14中呈现的组成。
[表14]
| 组分 | 含量(重量％) |
| 由化学式(1)表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 2.00 |
| 羟乙基纤维素(2％水溶液) | 12.00 |
| 黄原胶(2％水溶液) | 2.00 |
| 1,3-丁二醇 | 6.00 |
| 浓缩甘油 | 4.00 |
| 透明质酸钠(1％水溶液) | 5.00 |
| 纯净水 | 余量 |
| 总共 | 100.00 |
[制剂例11]软胶囊剂
将50mg由化学式(1)表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3与80至140mgL-肉碱、180mg大豆油、2mg棕榈油、8mg氢化植物油、4mg黄蜡和6mg卵磷脂混合，通过常规方法以每个胶囊400mg将混合物填充在胶囊中，由此制备软胶囊剂。
[制剂例12]片剂
将50mg由化学式(1)表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3与200mg低聚半乳糖、60mg乳糖和140mg麦芽糖混合，通过使用流化床干燥器将混合物制粒，向颗粒中加入6mg糖酯，并通过使用压片机将混合物形成片剂。
[制剂例13]颗粒剂
将50mg由化学式(1)表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3与250mg无水结晶葡萄糖和550mg淀粉混合，通过使用流化床颗粒机将混合物形成颗粒，并将颗粒装于袋中，由此制备颗粒剂。
[制剂例14]保健饮料
将50mg由化学式(1)表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3与10g葡萄糖、0.6g柠檬酸和25g液体寡糖混合，向混合物中加入300ml纯净水，并以每瓶200ml将由此获得的混合物装于瓶中。其后，将瓶装饮料在130℃下杀菌4至5秒，由此制备保健饮料。
虽然本发明已描述了具体的实施方案，但对于本领域技术人员会清楚的是，以上实施方案并非限制性的而是说明性的，本发明的范围不限于此。因此，应当理解，本发明的实际范围会由所附的权利要求书及其等同物所限定。
Claims (7)
1.由以下化学式(2)表示的21-O-当归酰基茶皂醇E3在制备用于抑制皮脂腺中皮脂的过度分泌的组合物中的用途，其中所述皮脂的过度分泌是由5α-还原酶产生的二氢睾酮引起的副作用：
[化学式2]
2.根据权利要求1所述的用途，其中茶皂醇衍生物衍生自绿茶皂苷。
3.根据权利要求1所述的用途，其中活性成分的含量是基于所述组合物总重量的0.001重量％至20重量％。
4.根据权利要求1所述的用途，其中所述组合物抑制5α-还原酶活性。
5.根据权利要求1所述的用途，其中所述组合物是药物组合物。
6.根据权利要求1所述的用途，其中所述组合物是化妆品组合物。
7.根据权利要求1所述的用途，其中所述组合物是食品组合物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150045133A KR102429834B1 (ko) | 2015-03-31 | 2015-03-31 | 티아사포제놀 유도체를 유효성분으로 포함하는 조성물 |
| KR10-2015-0045133 | 2015-03-31 | ||
| PCT/KR2016/003038 WO2016159580A1 (ko) | 2015-03-31 | 2016-03-25 | 티아사포제놀 유도체를 유효성분으로 포함하는 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107635561A CN107635561A (zh) | 2018-01-26 |
| CN107635561B true CN107635561B (zh) | 2020-08-04 |
Family
ID=57005194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680025742.7A Active CN107635561B (zh) | 2015-03-31 | 2016-03-25 | 含有茶皂醇衍生物作为活性成分的组合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20180078482A1 (zh) |
| KR (1) | KR102429834B1 (zh) |
| CN (1) | CN107635561B (zh) |
| HK (1) | HK1243927A1 (zh) |
| WO (1) | WO2016159580A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108840964B (zh) * | 2018-05-24 | 2021-02-19 | 华南理工大学 | 一种茶皂苷锗配合物、茶皂苷锗纳米颗粒及其制备方法和应用 |
| CN108743607B (zh) * | 2018-05-24 | 2021-02-12 | 华南理工大学 | 一种茶皂苷硒配合物、茶皂苷硒纳米颗粒及其制备方法和应用 |
| CN110694547A (zh) * | 2019-10-31 | 2020-01-17 | 宁夏回春生物科技有限公司 | 一种甘草表面活性剂及制作方法 |
| CN113216979B (zh) * | 2021-05-10 | 2024-03-08 | 华能澜沧江水电股份有限公司 | 一种裂隙岩体的微生物加固方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130118507A (ko) * | 2012-04-20 | 2013-10-30 | (주)아모레퍼시픽 | 녹차 종자 유래의 ２１-ｏ-안젤로일데아사포젠올 ｅ３ 성분을 함유하는 항노화용 피부 외용제 조성물 |
| KR20130119212A (ko) * | 2012-04-23 | 2013-10-31 | (주)아모레퍼시픽 | 녹차 종자 유래의 ２１-ｏ-안젤로일데아사포젠올 ｅ３ 성분을 함유하는 항산화 또는 미백용 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100755427B1 (ko) * | 2006-03-20 | 2007-09-04 | 주식회사 생그린 | 피부 탄력 증진 효과를 갖는 녹차씨 오일을 함유하는화장료 조성물. |
| KR101415995B1 (ko) | 2008-09-08 | 2014-07-08 | (주)아모레퍼시픽 | 녹차 사포닌 21-ｏ-안젤로일티아사포제놀 ｅ3의 제조방법 |
| KR101263547B1 (ko) * | 2010-04-08 | 2013-05-13 | 인제대학교 산학협력단 | 녹차씨 껍질 추출물을 유효성분으로 함유하는 항산화 또는 항염 활성을 갖는 화장료 조성물 |
| KR101824897B1 (ko) * | 2011-09-30 | 2018-02-05 | (주)아모레퍼시픽 | 차나무 뿌리 유래 사포닌을 함유하는 피부 외용제 조성물 |
-
2015
- 2015-03-31 KR KR1020150045133A patent/KR102429834B1/ko active IP Right Grant
-
2016
- 2016-03-25 WO PCT/KR2016/003038 patent/WO2016159580A1/ko active Application Filing
- 2016-03-25 US US15/561,560 patent/US20180078482A1/en not_active Abandoned
- 2016-03-25 CN CN201680025742.7A patent/CN107635561B/zh active Active
-
2018
- 2018-03-12 HK HK18103415.1A patent/HK1243927A1/zh unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130118507A (ko) * | 2012-04-20 | 2013-10-30 | (주)아모레퍼시픽 | 녹차 종자 유래의 ２１-ｏ-안젤로일데아사포젠올 ｅ３ 성분을 함유하는 항노화용 피부 외용제 조성물 |
| KR20130119212A (ko) * | 2012-04-23 | 2013-10-31 | (주)아모레퍼시픽 | 녹차 종자 유래의 ２１-ｏ-안젤로일데아사포젠올 ｅ３ 성분을 함유하는 항산화 또는 미백용 조성물 |
Non-Patent Citations (1)
| Title |
|---|
| 痤疮的药物治疗进展;安琪等;《中国医药导报》;20120630;第9卷(第18期);第10-12页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016159580A1 (ko) | 2016-10-06 |
| KR102429834B1 (ko) | 2022-08-05 |
| CN107635561A (zh) | 2018-01-26 |
| US20180078482A1 (en) | 2018-03-22 |
| KR20160116833A (ko) | 2016-10-10 |
| HK1243927A1 (zh) | 2018-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107635561B (zh) | 含有茶皂醇衍生物作为活性成分的组合物 | |
| JP2005220084A (ja) | アセロラ種子抽出物含有組成物 | |
| KR100773856B1 (ko) | 나한과 추출물 또는 이로부터 분리된 트라이터펜계화합물을 함유하는 주름개선용 조성물 | |
| CN103547250A (zh) | 黄酮类化合物的新用途 | |
| KR20200057677A (ko) | 청호, 병풀 및 녹차의 혼합 추출물 또는 이의 분획물을 유효 성분으로 함유하는 피부 상태 개선용 조성물 및 이를 이용한 피부 상태 개선 방법 | |
| CN107412031B (zh) | 含有橘皮素的皮肤外用剂组合物 | |
| KR102029078B1 (ko) | 새로운 올리고당 화합물 및 이의 미용학적 용도 | |
| KR20210058772A (ko) | 탈모 치료 및 발모 촉진용 조성물 | |
| KR101233910B1 (ko) | 탈모 방지 또는 발모 촉진용 조성물 | |
| CN112638395A (zh) | 作为有效成分含有樗白皮提取物的痤疮皮肤改善用或者皮脂分泌抑制用组合物 | |
| JP6267957B2 (ja) | 皮脂合成抑制剤 | |
| KR102445830B1 (ko) | 밀싹추출물을 유효성분으로 포함하는 피부 보습용 화장료 조성물 | |
| KR101233944B1 (ko) | 탈모 방지 또는 발모 촉진용 조성물 | |
| KR102348047B1 (ko) | 복숭아 새싹 추출물을 포함하는 피지 분비 억제용 조성물 | |
| KR101273027B1 (ko) | 캄페롤을 유효성분으로 함유하는 피지 분비 억제용 및항비만용 조성물 | |
| KR20160036119A (ko) | 마린콜라겐, 다시마, 모즈쿠, 클로렐라, 모자반, 연어알, 캐비어로 구성된 추출물을 유효 성분으로 함유하는 화장료 조성물 | |
| JP5000964B2 (ja) | テストステロン５α−リダクターゼ活性阻害剤、アンドロゲンレセプター拮抗剤、その用途、及びアンドロゲン活性発現の抑制方法 | |
| JP6386053B2 (ja) | ２１‐ｏ‐アンゲロイルテアサポゲノールｅ３を含む発毛または育毛促進用組成物 | |
| KR20230024456A (ko) | 인삼 열매와 녹용을 포함하는 피부 보습, 주름 개선 또는 상처 치유용 조성물 | |
| KR102212343B1 (ko) | 마리안 플럼 추출물을 유효성분으로 함유하는 피부 항노화 및 보습용 조성물 | |
| JP2006089385A (ja) | 美肌用組成物 | |
| TW201617065A (zh) | 含高山黃芩萃取物之美白肌膚組成物 | |
| JPH10330218A (ja) | メラニン産生促進剤並びにこれを含有する皮膚及び毛髪用外用剤 | |
| KR101832862B1 (ko) | 산속단 추출물을 유효성분으로 함유하는 피부 미백용 조성물 | |
| KR20160053173A (ko) | 모시근 추출물을 유효성분으로 함유하는 피부 주름 생성 억제 및 개선용 화장료 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1243927 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |